Immunic, Inc. (IMUX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$9.44+$0.1199 (+1.29%) on the dayAs of the close; data may be delayed.
IMUX price, last 12 months
Key stats
- Previous close
- $9.32
- Open
- $9.50
- Day range
- $9.12 – $9.50
- 52-week range
- $5.06 – $17.43
- Volume
- 300.1K
- Avg volume (20 days)
- 382.6K
- Market cap
- $127.5M
Performance
1W−11.1%
1M−42.8%
3M−38.3%
6M−25.1%
YTD+76.9%
1Y+7.4%
vs S&P 500, 1Y−9.4 pts
Technicals and fundamentals
About Immunic, Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $127.5M